242 related articles for article (PubMed ID: 10722429)
21. Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis.
Lu CL; Chuang YC; Chang HC; Chen YC; Wang JT; Chang SC
J Antimicrob Chemother; 2012 Sep; 67(9):2243-9. PubMed ID: 22618861
[TBL] [Abstract][Full Text] [Related]
22. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium.
Linden PK; Pasculle AW; Manez R; Kramer DJ; Fung JJ; Pinna AD; Kusne S
Clin Infect Dis; 1996 Apr; 22(4):663-70. PubMed ID: 8729206
[TBL] [Abstract][Full Text] [Related]
23. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation.
Kapur D; Dorsky D; Feingold JM; Bona RD; Edwards RL; Aslanzadeh J; Tutschka PJ; Bilgrami S
Bone Marrow Transplant; 2000 Jan; 25(2):147-52. PubMed ID: 10673672
[TBL] [Abstract][Full Text] [Related]
24. Identification of temporal clusters and risk factors of bacteremia by nosocomial vancomycin-resistant enterococci.
da Silva NS; Muniz VD; Estofolete CF; Furtado GH; Rubio FG
Am J Infect Control; 2014 Apr; 42(4):389-92. PubMed ID: 24679566
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for prolonged carriage of vancomycin-resistant Enterococcus faecium among patients in intensive care units: a case-control study.
Yoon YK; Lee SE; Lee J; Kim HJ; Kim JY; Park DW; Sohn JW; Kim MJ
J Antimicrob Chemother; 2011 Aug; 66(8):1831-8. PubMed ID: 21652622
[TBL] [Abstract][Full Text] [Related]
26. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci.
Scheetz MH; Qi C; Noskin GA; Warren JR; Postelnick MJ; Malczynski M; Huang J; Zembower TR
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):407-13. PubMed ID: 16930924
[TBL] [Abstract][Full Text] [Related]
27. Recurrent vancomycin-resistant Enterococcus bacteremia: prevalence, predisposing factors, and strain relatedness.
Baran J; Riederer KM; Ramanathan J; Khatib R
Clin Infect Dis; 2001 May; 32(9):1381-3. PubMed ID: 11303278
[TBL] [Abstract][Full Text] [Related]
28. A 10-year profile of enterococcal bloodstream infections at a tertiary-care hospital in Japan.
Suzuki H; Hase R; Otsuka Y; Hosokawa N
J Infect Chemother; 2017 Jun; 23(6):390-393. PubMed ID: 28385565
[TBL] [Abstract][Full Text] [Related]
29. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
Mohr JF; Friedrich LV; Yankelev S; Lamp KC
Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
[TBL] [Abstract][Full Text] [Related]
30. First report of clinical and epidemiological characterisation of vancomycin-resistant enterococci from mainland China.
Cao B; Liu Y; Song S; Li R; Wang H; Wang C
Int J Antimicrob Agents; 2008 Sep; 32(3):279-81. PubMed ID: 18614337
[No Abstract] [Full Text] [Related]
31. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium.
Pai MP; Rodvold KA; Schreckenberger PC; Gonzales RD; Petrolatti JM; Quinn JP
Clin Infect Dis; 2002 Nov; 35(10):1269-72. PubMed ID: 12410489
[TBL] [Abstract][Full Text] [Related]
32. Nosocomial outbreak of vancomycin-resistant Enterococcus faecium in a paediatric unit at a Turkish university hospital.
Ergani-Ozcan A; Naas T; Baysan BO; Ogunc D; Inan D; Colak D; Nordmann P
J Antimicrob Chemother; 2008 May; 61(5):1033-9. PubMed ID: 18319236
[TBL] [Abstract][Full Text] [Related]
33. Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital.
Werner G; Klare I; Spencker FB; Witte W
J Antimicrob Chemother; 2003 Jul; 52(1):113-5. PubMed ID: 12805253
[TBL] [Abstract][Full Text] [Related]
34. Emergence of VanD-type vancomycin-resistant Enterococcus faecium in Stockholm, Sweden.
Fang H; Hedin G; Telander B; Li G; Nord CE
Clin Microbiol Infect; 2007 Jan; 13(1):106-8. PubMed ID: 17184299
[TBL] [Abstract][Full Text] [Related]
35. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.
Rahim S; Pillai SK; Gold HS; Venkataraman L; Inglima K; Press RA
Clin Infect Dis; 2003 Jun; 36(11):E146-8. PubMed ID: 12766857
[TBL] [Abstract][Full Text] [Related]
36. Case of vancomycin-resistant Enterococcus faecium infection associated with a transjugular intrahepatic portosystemic shunt that was treated with quinupristin/dalfopristin after bacteremia persisted with alatrofloxacin therapy.
Zaman MM; Recco R; Tejwani U; Scuto TJ; Ahmed S; Hypolite A; Jayaraman G
Clin Infect Dis; 1999 Oct; 29(4):954-5. PubMed ID: 10589932
[No Abstract] [Full Text] [Related]
37. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk.
Worth LJ; Thursky KA; Seymour JF; Slavin MA
Eur J Haematol; 2007 Sep; 79(3):226-33. PubMed ID: 17655696
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci.
Zaas AK; Song X; Tucker P; Perl TM
Clin Infect Dis; 2002 Nov; 35(10):1139-46. PubMed ID: 12410472
[TBL] [Abstract][Full Text] [Related]
39. [Study of a cohort of patients with Enterococcus spp. Bacteraemia. Risk factors associated to high-level resistance to aminoglycosides].
García-Vázquez E; Albendín H; Hernández-Torres A; Canteras M; Yagüe G; Ruiz J; Gómez J
Rev Esp Quimioter; 2013 Sep; 26(3):203-13. PubMed ID: 24080886
[TBL] [Abstract][Full Text] [Related]
40. [Bacteremia caused by Enterococcus gallinarum with a high level of glycopeptide resistance: 1st documented cases in Argentina].
Togneri A; Lopardo H; Corso A
Rev Argent Microbiol; 2003; 35(2):96-9. PubMed ID: 12920991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
